Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Per the 10-Q (near the bottome), the company expects to move Eltoprazine studies forward, commercialize LymPro and further the MAN pre-clinical studies.
Where is the ESS clinical trial startup promised for Q3?
Very accurate assessment! Its time for change and new leadership. Lets see if the BOD is willing to invoke a leadership change at the top .....or is it just a good ole boy network. GC has brought a lot of talent that to AMBS that has been wasted ....so even some of those employees that were hired should be removed (and new ones hired).
As I would even go beyond to say that it might be time for the BOD to be replaced next too. In the world of publicly traded companies; leaders are not given carte blanche to make things right or turn them around indefinitely.....its very embarrassing to say the least. The shareholders deserve better!
Officially, the NASDAQ listing application has been filed (and even confirmed by JN per the 8k filed yesterday ...and via the latest AMBS investor presentation that is posted to the company website). Mgt. is awaiting feedback from NASDAQ as we speak.
Sentiment can change quickly......dont fall asleep on this one. Once they take the leap on to NASDAQ; getting quality financing will be a thing of the past. And you will see how the new institutional base will buy and assign the true market value for the quality assets that AMBS has in its pipeline.
If the company successfully makes it to NASDAQ; it will be a major paradigm shift for the company. I still believe that the huge drop in the PPS was manipulative in nature (and quite possibly a situation which allowed the Institutions in the know that great things are coming and an opportunity to accumulate....it happens on the Street every day).
Could see one last retest below $3 (intraday); and we should see the PPS recover. Since the sentiment has been so negative; its ripe for a positive surprise in the near future. Lastly, when there is "Blood in the street" ....it does create an attractive investment opportunity and a transfer of wealth to those who are savvy enough to take it.
ESS News release this morning (expanded partnership). Where is the $$$ - funding? They expanded the agreement; yet there is still no mention or any updates on the existing or new funding. I still dont see how this does anything for the stock price.
Gerald - focus your time on raising money please (Non Dilutive)!!!!!
I think its bad timing to have the Annual meeting at the Nasdaq site area. If there could have been one right decision; it would have been best to have the meeting on the other side of the world (that way no shareholders could attend). Oh well!
JP:
I always look forward to your posts and typically you are spot on. My biggest problem is the "go it alone". The strategy just doesnt work for a small penny stock and company that requires massive capital to progress a pipeline.
Mgt. should be able to attract a high quality venture capital firm that truly believes in the Science. Everyone can still reach the same goals and make alot of money.
But most importantly, when a CEO blatantly has lied the way this one has..its time to go and be replaced (or per my advice...just take the company private and then the shareholders wont need to know and care how the business is orchestrated since it wont be publicly traded).
Note: MS Precise was to be commercially viable later this year...when did that all change? Can someone please help me understand why the expectation was built that way? So in reality, the CEO doesnt have a clue. LymPro was to garner a huge % of the RUO market? How does the CEO think that is true but an Analyst at Zacks had already figured out that it cant garner more than $1mm in potential sales. Somebody is not telling the truth...who seems to repeat the mistakes over and over?
I appreciate your response. I guess how success is measured is based on either short term or long terms perspectives (and stock price performance). If you feel that Gerald's performance is spectacular and the shares are cheap; please tell are more credible and respected board to get off their asses and start buying shares down here at these levels.
Make sense? I would think Joe R. and Dave L. have some extra funds to do so. Agree?
Interesting summary jrock777!
1) So why is Wall Street so unimpressed with this stated progress? Which the PPS clearly reflects right now?
2)Why do you think that their has not been any venture capital or solid institution will to ante up $30mm or $40mm to fund this pipeline? Other than toxic funding?
3) Do you think the CEO is too eager to bring this vast pipeline forward without any partnerships...knowing both short term and medium term it will require MASSIVE dilution? ESS is the perfect candidate (in my humble opinion)?
4) Is the BOD sleeping....too interested in their own personal endeavors and just collecting paychecks?
5) How long should any CEO have to prove himself? What do you think the NASDAQ oriented institutions might do if Gerald shows the same performance when potentially Uplisted?
6) LymPro seems like a yawner; why invest so much time, resources with this asset? Lets progress the Georgetown assets and move a credible asset with stronger performance forward (and potential).
7) You can buy every (and any asset in the world and from any other business. But if you dont have any fundamental and meaningful financing plan what good is it to have them?
Poor leadership translates to a suffering stock price. Reality 101.....if you want to give credit for these accomplishments...perhaps AMBS would be better served as a private entity (but its not my friend..and thats a SERIOUS problem).
Either the Market is speaking and it doesnt like what it sees and hears. Or this is just classic of manipulative BS (by the Market makers). If we ended up at 35mm OS post Uplist (I would not be disappointed). I do think too many here still think in terms of pre Split #'s.
My advice: if Gerald would just retain family ownership of the company and let someone else run it...that wouldnt hurt either.
To Mgt.: Some insider buys would send quite a message to shareholders (and I am not talking buying 1K shares). Several board members should be buying 5 or 10k blocks right now to show their vote of confidence in their future business plan.
I would tend to agree with this type of volume. Gerald needs to realize that he cant bring forward a vast pipeline without proper funding. Therefore, I would partner ESS and get upfront money and a royalty agreement.
There will be many ore opportunities to buy distressed assets down the road. Also, if he performs this way once he is on NASDAQ; what do you think the Institutions will do and say? He can only get away with this mediocre performance for so long; his luck will run out one way or another.
JP: Great points! A lesson learned for me with buying stock of a Mom and Pop shop. Its better to have an independent CEO (with an incredible network of peers and impressive track recording working directly within the Pharmaceutical industry).
Answer: Dr. Lowe would make a great fit....Gerald...are you listening?
Roche is too big to get into details about every product/drug. Obviously, the SC versions are not their flagship drugs or core revenue drivers. Hopefully, HALO mgt. might add some color to the situation and reality.
JP: Its all about rightsizing the ship here. Too me - the focus has to come off LymPro ..and now to how they will fund Phase 2 Eltoprazine and ESS assets. If Mgt. can simply find a way to raise a respectable amount of cash ...other than via dilution. It can still all work out.
If ESS is as great as many 3rd parties are projecting and speculating; then Mgt. should partner and get some upfront money to do the trials. Wall street has spoken; and its not working for Gerald and the team right now.
Last recommendation; can have the CEO just be humble and recognize that he is in over his head now.
If Gerald brought in someone with a proven track record and a solid background. The PPS will stabilize and start heading back up.
Life is always full of tough decisions; hopefully, he will make the right one this time around and for his shareholders.
Under normal circumstances; I would agree...but you cant forget who both owns and runs the company. Gerald (and father) arent going anywhere anytime soon (unless its sold outright).
I think Gerald has been given enough time to prove himself. I think what happens with the latest LymPro results will speak greatly as to what success he can deliver under his stewardship.
It LymPro bombs (jury is still out); it might be best for him to move more into a Chairmanship role where he hires a full blown CEO to run the entire company (but he can still have control of AMBS and his future...but he wouldnt be responsible for daily execution and delivery).
Also, the market is telling an interesting story here; as there has been no run up in the stock price heading into the latest LymPro results due at AAIC (like the movie Jerry McGuire; its show me the $$ time for Gerald...glad to see Wall street has the stock price in a check). Believe it or not...put up or shut up time indeed.
Gerald has not been credible...I cant deny that reality. But watch the tables turn when he is held accountable by potentially large institutional investors who will invest in the company shortly (he wont have any leeway as he did before...the investing history here is a live and learn).
But until you sell; it really doesnt matter what happened to the stock price over the last year or two. The pending LymPro news will be quite interesting....but either way if LymPro works or doesnt...it will just take an adequate financing plan to move Eltoprazine and ESS assets forward (could quadruple in market value overnight... if that happens).
It could take years before they hit the 35mm threshold. I think their are a lot of pending news transactions that will move us up right into an August Uplisting. For those who have suffered and shared in the pain with the dropping stock price....it could swing back the other way and equally move upward. Stay tuned!
Answer: If you were a large institutional investor and wanted to take a position; but you realized that the current # of authorized shares wouldnt allow you any liquidity to trade in and out of the stock. Major wall street investment firms are strong proponents to invest in companies with a proper amount of authorized and outstanding shares.
Are folks serious that you think 7mm outstanding shares is an ideal # based on current market standards. Also, as they get ready to prepare for the IPO...they will have additional shares come on to the market.
So if we settle at no more than 35mm; I will be whistling dixie.
In my opinion, the so perceived big news will happen either leading into the IPO or post the Uplisting to Nasdaq. The big investors get rewarded...not the retail crowd.
The recent financing bodes well that some very positive things are in the works...so good points JP that the financing is extremely positive. We need to get significant LymPro news to catapult the stock price....I am very optimistic that the Sensitivity and Specificity will improve tremendously this time around
.......Warren Buffet...."Buy when there is blood in the street"s...we were just there and are still in that reality...have to BELIEVE we go up from here.
Why are some so enamored with the "D" at the end of the symbol. It simply means that the stock just has a Reverse split. It has nothing to do with news releases whatsoever.
JP: My two cents; I knew the PPS would sell off post R/S ...9 out of 10 of them do when their is no follow up news (that is significant). However, I believe the dark period is almost over.....so selloff, stabilization (we are in this phase now), attempts to ascend with a few bumps or slight pullback, good news is released and off we go.
HOLD in there longs; the sun will come up one day soon.
You are looking in the rearview mirror. The ADX spinoff will generate the needed cash ...BE READY!
My Scottrade shares are now fully converted post R/S (as of the market close). I am ready for our new future and looking to possibly add on Monday (will watch to see if their is some imminent weakness now that all the shares should be converted by Monday).
Most importantly, its hard to handicap what will happen with everyone having the capability to sell now; (which I believe is what happened for some who had shares converted earlier in the day). GLTA!!
Good communication by the CEO...investors starting to get concerned about the timing of R/S once again. It looks like it will be Wed or Thurs. AM. Its a start of a new chapter for this company...and please dont underestimate how much upside this pipeline has once funded properly. GLTA!!!
Thank you for posting this most meaningful information. Hoping the best for Halozyme and most importantly...the patients who need new therapies and drugs.
It will be pure delight once the AMBS is Up listed. The bashing will turn into admiration ...and many will need to look for another culprit to bash.
Exciting times ahead for this rich pipeline......my worries have turned into how I can best increase my position as soon as possible. Buy now or post R/S ..once those institutional buyers come knocking; you will be wishing that you bought every share possible at $.05.
Buffet: Buy when their is blood in the streets...so true!!!
Excellent post! Jason N. seems to get the bigger picture than most ...I think investors have to start recognizing all of the upside potential ...versus thinking about any downside. Its been a long road here for all...so I understand why confidence is shattered right now.
But for those who can connect the dots....there is a lot of potential money to be made here for those who can understand the situation and upside both S/T and L/T. GLTA!!
We are going into unchartered territory with everything going on; I like that the Institutions can buy ahead of the IPO. I would like the R/S completed immediately...lets start the party now.
Honestly, I believe it could go above $.07 tomorrow (unless the forces keep it near $.05). The company and stock price is grossly undervalued ...no matter how you analyze it many ways.
The kicker...the LymPro situation has changed significantly for the better.....I am thinking that was staged until they got on to the Nasdaq one way or another.
I strongly believe the O/S will increase above 7 mm. Lets see what ADX transactions occur that might affect and/or increase the O/S count. Its very possible that the company does an official IPO on the main Nasdaq exchange...converting all the low tier Nasdaq shares into the big Nasdaq exchange.
Example. I owned Neopharm ...was on the Pink sheets and converted into the OTCBB (on a 1 to 61 RS). Eventually, Neopharm was merged completely into Insys Therapeutics did an IPO on Nasdaq at $8 a share. Hence, the Neopharm OTCBB shares were converted once again into INSY stock.
Insys went from $8 to $84 in less than 4 months (with a higher O/S count). Go figure!!!
Did you read the news release this AM?. Re read it!!!! They are in late stages with completing a Diagnostic divisions strategic transaction.....you are missing other pieces of the puzzle.
My worst fear...the company is saving the blockbuster news for post the R/S ...as a reward mechanism for the new institutional investor base. I have seen this happen so many times before.......but who knows how this will play out (but no matter what....by the end of next Wed.; we will have all of our answers or maybe even by tomorrow).
I am surprised on the timing; as tomorrow will be a rather uneventful trading day on Wall street (pre Memorial weekend vacation time for many traders).
Great question!. Perhaps its just a filing and intention to R/S the shares (sort of like increasing your Authorized shares but never using all of them). We dont know what transactions might occur before the R/S split is triggered:
1) Could they have sold the Diagnostic division?
2) Could ESS (Cutagen) be sold)? Interesting how that deal never closed yet...could have been courting buyers and wanted the best deal. I still dont think this asset is a strategic fit into the company anyway.
3) Could we have a Partnership somewhere aligned to one of our most signficant assets (MANF - RP, Eltoprazine, ESS or maybe even on LymPro)?
Its possible that we wake up tomorrow and the R/S is already converted at a $.05 or $.055 strike price...and we are Up listed on Nasdaq next Tuesday or Wednesday. Its very interesting how the Conference call (next Wed.) was delayed a week after the actual Q1 Earnings announcement.
Stay tuned!!!
Reasons:
1) Major dilution
2) Need to Uplist to a Majo exchange
3) Need cash
When dilution stops and we are Uplisted....with any respectable infusion of cash...off we go. Stay tuned!
Market makers loading up ahead of news; they are eliminating overhead supply ahead to move PPS higher as quickly as possible. Also, the chart reflects that a strong bottom is in too.
And volume always precedes price; I am back to adding to an already large position (which has been put on hold for many months). Upgrading from Hold...back to Accumulate. Cheers!
New financing is a good sign; I like to see some other quality institutions do financing deals with Amarantus. Also, the conversion price is higher than the market value price (at $.06). Honestly, I think the bottom is in at these levels....this has been a painful journey but its still one that can have a happy ending.
Everyone is promising to fix the worlds Alzheimers problems as the topic heats up and is on the forefront on a daily basis. Lets talk about it once its CLIA/FDA approved and selling....but thanks resident expert for your valued analysis.
For someone who doesnt have anything good to stay; you sure spend a lot of time and energy following the PPS. What gives?
I would say that a significant amount of any dilution are tied to the most recent acquisitions..Diogenix and the ESS burn asset.
So yes, there will be dilution along the way; but I dont think the massive amount of diluted shares that are tied to the big money payouts (for these acquired assets)..... can be converted yet. The 10-K will say it all...I am thinking around 1 billion or slightly higher.